Objective: Mitochondrial dysfunction and energy metabolism impairment are key components in the pathophysiology of bipolar disorder (BD) and may involve a shift from aerobic to anaerobic metabolism. Measurement of brain lactate in vivo using proton magnetic resonance spectroscopy ( 1 H-MRS) represents an important tool to evaluate mitochondrial and metabolic dysfunction during mood episodes, as well as to monitor treatment response. To date, very few studies have quantified brain lactate in BD. In addition, no study has longitudinally evaluated lactate using 1 H-MRS during depressive episodes or its association with mood stabilizer therapy. This study aimed to evaluate cingulate cortex (CC) lactate using 3-T 1 H-MRS during acute depressive episodes in BD and the possible effects induced by lithium monotherapy.
nergy metabolism dysfunction has been considered a key component of the pathophysiology of bipolar disorder (BD).
1,2 Evidence for this metabolic dysfunction includes lower brain intracellular pH and phosphocreatine in BD. 3 Brain lactate has a key role in neural energy metabolism, and its altered concentrations may represent a less severe form of mitochondrial and metabolic dysfunction. 4, 5 In addition, a different line of evidence showing increased oxidative stress 6, 7 and impaired expression of mitochondrial genes in BD 8, 9 provides further support to the role of mitochondrial and redox dysfunction leading to a shift toward anaerobic metabolism and associated elevated risk for cellular injury. 10, 11 Proton magnetic resonance spectroscopy ( 1 H-MRS) provides a noninvasive technique to measure brain lactate in vivo in psychiatric research. In BD, previous studies during mood episodes (manic and depressed) and euthymia have shown mixed results. 5, 12, 13 In a cross-sectional study, Dager et al 5 found an increase in gray matter (GM) lactate concentrations in medication-free BD patients with long-term illness and predominantly in a depressed or mixed state. Brady et al 13 found similar lactate levels in the anterior cingulate cortex (CC) during mania (n = 15) compared with control subjects. Seven medicated patients underwent a subsequent follow-up scan (average follow-up time, 21.1 months) while in euthymia and showed lower anterior CC lactate compared with matched control subjects. This is a key area involved in mood regulation and is a target for lithium's biological effects.
14 A recent study emphasized that lactate is primarily localized in the CC (and caudate) of subjects with BD. 15 Lithium is the mainstay of pharmacotherapy for acute mood episodes, prophylactic treatment, and suicide prevention in BD. 16 Data from the European drug surveillance program describe that lithium is the most frequently prescribed agent for bipolar depression in combined therapy (33%). 17 Lithium modulates key mitochondrial proteins and prevents and/or reverses DNA damage, free radical formation, and lipid peroxidation. 16, 18, 19 Lithium has also been shown to improve synaptic strength, cellular resilience, and glial function. 11, 20 Interestingly, in a crosssectional MRS study, Friedman et al 21 described similar brain lactate concentrations in BD subjects taking lithium compared with healthy controls. In mania, Kim et al 12 observed a significant decrease in midfrontal cortex lactate in subjects with BD treated with quetiapine for 12 weeks; this finding was associated with the antimanic response.
In the present study, CC lactate was evaluated in medicationfree BD subjects in a major depressive episode before and after 6 weeks of lithium monotherapy using 3-T 1 H-MRS. Furthermore, although a few studies evaluated brain lactate in BD, no study has either longitudinally evaluated lactate using 1 H-MRS during a specific mood state (mania or depression) or assessed its association with lithium monotherapy treatment response in drug-naive BD subjects.
We hypothesized that BD subjects would have increased lactate in the CC, as measured by multivoxel 3-T 1 H-MRS during bipolar depression compared with control subjects and that reductions in lactate with lithium treatment would be associated with treatment response.
METHODS Participants
Fifty-nine individuals prescreened by phone interviews were evaluated at the outpatient clinic of the Mood Disorders Group (LIM-27), Department and Institute of Psychiatry, University of São Paulo. Twenty-six subjects fulfilled criteria for the present study and were enrolled. Six BD subjects were excluded because of the following reasons: 2 patients dropped out before the completion of a 6-week follow-up, whereas 4 subjects had technical issues (data collection) at either baseline or follow-up 1 H-MRS scan, which limited a complete postprocessing data analysis. Thus, our final sample consisted of 20 medication-free subjects (80% treatment naive) with BD in a major depressive episode (16 women and 4 men, aged 22-43 years old) who completed the 6-week lithium trial.
Subjects with BD in a depressive episode were included according to the following criteria: (a) age between 18 and 45 years, (b) diagnosis of BD I or II in a current major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), (c) score greater than 17 in the 21-item Hamilton Depression Rating Scale (HDRS), 22 (d) no previous use of lithium (lifetime) and absence of the use of any psychiatric medication or drugs with central nervous system (CNS) effects for at least 6 weeks, and (e) illness duration of no more than 5 years. Exclusion criteria included rapid cycling BD; current substance (including alcohol) abuse or dependence, with the exception of tobacco; previous electroconvulsive therapy; presence of neurological disorders or any medical disorder that could affect the CNS; mental retardation; medications with CNS effects; vitamins; and contraindications to magnetic resonance imaging scanning. 23 Patients were evaluated with a semistructured clinical interview and blood tests (including complete blood count, electrolytes, and renal and thyroid function). All patients were started on lithium carbonate (450 mg/d), and a systematic follow-up was carried out for 6 weeks. Visits for clinical assessment and plasma lithium monitoring in the plasma were performed at weeks 1, 2, 4, and 6. Subsequent dose adjustment was allowed, based on individual clinical efficacy and aiming to reach therapeutic levels of lithium (0.4-1.0 mmol/L). The 1 H-MRS scanning was performed at baseline (week 0) and endpoint (week 6) in BD patients and only at baseline in the matched control group.
The healthy volunteers group included 16 subjects (9 women and 7 men, aged 20-43 years old), all free of any psychiatric disorder (based on DSM-IV criteria) and with no history of mental disorders among first-degree relatives. Volunteers were recruited through advertisement in the local community. The local institutional review board approved this study, and all subjects provided informed written consent prior to participating in the study. This study was part of a multimodal investigation to evaluate central and peripheral therapeutic targets of lithium's antidepressant actions in BDs.
Clinical Measures
Experienced psychiatrists performed all clinical assessments. Psychiatric evaluation was performed in both patients and control subjects using the Structured Clinical Interview for DSM-IV. 24 A medical history was obtained directly from each participant and/ or family member. At each follow-up visit (weeks 1, 2, 4, and 6), the severity of depressive and manic symptoms was assessed using, respectively, the HDRS and the Young Mania Rating Scale. 25 Clinical response was defined as a decrease of 50% or greater in the HDRS, whereas remission was defined as an HDRS and Young Mania Rating Scale score of 8 or less. The global functioning at baseline and endpoint (improvement) was also assessed using the Clinical Global Improvement (CGI) scale. 26 Interrater reliability was greater than 0.9 for all rating scales. . Twelve individual voxels (2 columns of 6 voxels each) placed on the CC, as shown in Figure 1 , were selected for analysis. The MRS grid was placed on an axial slice just above the corpus callosum, following the anterior commissureposterior commissure angulation. The 12 individual spectra within the selected region of interest (ROI) were averaged and processed as a single spectrum. This method was shown to obtain significantly improved lactate measurement as compared with averaging chemical concentrations derived from the fitting of individual voxels in the ROI. 27 Spectral peak quantification was performed using the Spectroscopy Tool of the Extended MR Workspace R.2.6.3.5 (Philips Medical Systems) after phase adjustment, exponential line broadening of −1 Hz, and zero filling. The spectrum was fitted to the sum of 4 signals: choline (Cho), creatine (Cr), N-acetyl-aspartate (NAA), and the lactate double peak (Fig. 2) . Proton magnetic resonance spectroscopy was acquired at a long TE (288 milliseconds), to ensure that lipid and macromolecule signal were fully relaxed and did not overlap with the lactate signal. Lactate was quantified by the integral ratio of the lactate peak with the creatine peak. Quality criteria used for spectra inclusion were based on signal-to-noise ratio (SNR) measurements. Because lactate appears as an isolated peak with no overlap with other metabolite signals on a spectrum with a TE of 288 milliseconds, SNR is a convenient rejection criterion. 28 To investigate the brain tissue composition of the ROI, 3D volumetric images were obtained using the 3D-T1FFE technique (FA = 8°; TE/ repetition time/TI = 3.2/7/900 milliseconds) with isotropic resolution of 1 mm 3 . Briefly, the brain tissue was evaluated using the brain extraction tool, and segmentation into white matter (WM), GM, and cerebrospinal fluid (CSF) was achieved using the automated brain segmentation tool FAST, both apart of the FSL suite (http:// www.fmrib.ox.ac.uk/fsl). Finally, the ROI was overlaid on the segmented image using a Python-based script developed in-house, and percentages of WM, GM, and CSF were calculated for each ROI. The scanner used for this study is submitted to a weekly MRS quality control performed using a phantom with an aqueous solution of brain metabolites. The focus of this study was lactate. The long-TE MRSI acquisition used was chosen on purpose to measure a significantly high lactate signal, which otherwise is not observable in a single-voxel conventional MRS spectrum. The disadvantage of this long-TE acquisition is that short T2 metabolites, such as myo-inositol and glutamate + glutamine, are not measurable. For this purpose, we conducted a different MRS acquisition in the same population, which has already been published 29 and reporting results on all other metabolites.
H-MRS Scan and Data Processing

Statistical Analysis
The Kolmogorov-Smirnov test was used to verify the normality of the data within each study group. Between-group comparisons of continuous variables with a Gaussian distribution were performed with unpaired 2-tailed Student t test, whereas the Mann-Whitney U test was used for nonparametric data. The χ 2 test was used for the comparison of categorical variables. Changes in CC lactate and depressive symptoms over time were assessed with the paired-samples t test (normal distribution) or with the nonparametric Wilcoxon rank sum test (nonnormal distribution). Specifically for the comparison of CC lactate between BD patients both at baseline and at week 6 as well as control subjects, the analysis of covariance was carried out controlling the CSF fraction of the voxel as a covariate. Mixed-effects models were also used to investigate whether clinical variables and outcomes were associated with changes in brain lactate (dependent variable) after 6 weeks of lithium treatment. Finally, the correlation between brain lactate and clinical variables was evaluated using partial correlations controlling for the CSF fraction of the voxel. Pearson correlation coefficients or Spearman tests were used for additional correlations. All statistical analyses were performed using SPSS 21.0 (Chicago, IL) with a significance level set at P < 0.05 (2-tailed).
RESULTS
Demographic and Clinical Data
Demographic and clinical data for subjects with BD and control subjects are summarized in Table 1 . No significant difference in age (P = 0.29) or sex (P = 0.12) was observed when comparing BD subjects and control subjects. All patients were free of any psychotropic medication for at least 6 months prior to the enrollment in the study, and 16 (80%) had never received treatment with any mood stabilizer or antipsychotic agent (treatment naive). Mean lithium levels at week 6 were 0.48 ± 0.19 mmol/L. All patients were using therapeutic doses of lithium (600-900 mg/d; mean dose, 671.1 ± 115 mg). All patients had less than 5 years of illness duration (mean, 36.0 ± 18.7 months). Furthermore, there were significant changes in HDRS (baseline, 22.40 ± 3.01; endpoint, 7.90 ± 6.23; P < 0.001) and CGI scores (baseline, 4.00 ± 0.32; endpoint, 2.15 ± 0.87; P < 0.001) ( Table 1) . Twelve BD patients (60%) achieved remission at endpoint. No treatment-emergent affective switches or dropouts were observed.
CC Lactate in BD Versus Control Subjects
Subjects with BD in a depressive episode showed at baseline increased lactate in the CC compared with control subjects (F 1 = 4.32, P = 0.04; general linear model with the CSF fraction of the voxel as a covariate) ( Table 2 ). Cerebrospinal fluid fraction of the ROI also did not significantly vary across groups (BD patients = 0.17 ± 0.05 vs control subjects = 0.19 ± 0.06; t 34 = 1.16, P = 0.25). No difference between groups was also observed for WM (t 23 = 0.9, P = 0.37) and GM (t 23 = 1.32, P = 0.2) fractions of the ROI. No changes in CC lactate levels were observed when comparing drug-naive versus drug-free BD subjects (data not shown). Cingulate cortex lactate at baseline was not associated with any clinical outcome (total improvement, response, or remission).
CC Lactate in BD at Baseline Compared With Post-Lithium Treatment
A significant reduction in CC lactate was observed in BD patients after 6 weeks of lithium treatment compared with baseline (t 19 = −3.52, P = 0.002) ( Table 2 , Fig. 2 ). After lithium treatment, BD patients showed no difference in CC lactate when compared with control subjects (F 1 = 2.58, P = 0.11). When comparing patients pre-versus post-lithium treatment, no changes in CSF (t 19 = −0.98, P = 0.33), GM (t 19 = 1.64, P = 0.11), or WM (t 19 = −1.145, P = 0.16) were observed.
Predictors of Response
Baseline CC lactate did not correlate with any demographic and clinical variable described in Table 1 (partial correlation controlled for the CSF fraction of the voxel) (all not statistically significant), except for a positive association with family history of mood disorders (P = 0.02, r = 0.46). No significant correlations were observed between changes in CC lactate and HDRS and CGI scores over time or at endpoint (all not statistically significant). Mixed-effects model analysis revealed no significant association between remission status at endpoint and the change in CC lactate over time (F = 1.62, P = 0.211).
Associated Biological Findings
Changes in lactate were not associated with clinical improvement (HDRS score change) (P = 0.5). Plasma lithium at endpoint was not associated with lactate at endpoint (week 6) (P = 0.2) but was negatively associated with changes in lactate levels over time (P = 0.04, r = −0.43).
DISCUSSION
To the best of our knowledge, our study is the first longitudinal 1 H-MRS study to evaluate CC lactate concentrations in medication-free patients with acute bipolar depression before and after treatment with lithium. As hypothesized, based on evidence supporting a key role for brain energy metabolism dysfunction with a shift toward anaerobic metabolism in BD, 2, 20 we found increased CC lactate levels in subjects with BD during a depressive episode compared with matched control subjects. The CC is part of the frontal-subcortical circuit that has a critical role in mood regulation in BD. Similar to our findings, Dager et al 5 described an increase in GM lactate in an axial section focused around the anterior cingulate in BD, which was not associated with improvement in depression. 5 Likewise, in a recent study using 2D 1 H-MRS, a significant increase in brain lactate in medication-free BD subjects in mania (n = 12) and bipolar depression (n = 12) was found regardless of the brain region when compared with control subjects. 30 In the same context, decreased frontal lobe pH was observed in BD patients and has been directly associated with lactic acidosis. 1 Indeed, cytosolic production of lactate is regulated by mitochondrial oxidative processes occurring during pathological conditions such as acute mood episodes. The elevated conversion of glucose to lactate implies that little glucose is available for biosynthesis or mitochondrial oxidation and that lactate may serve as a metabolic substrate to neurons. In this circumstance, lactate is taken up and used in highly oxidative neurons because of changes in mitochondrial redox status. This shift aims to provide supplementary fuel source to neural cells.
In contrast to a previous study showing no changes in brain lactate levels in BD subjects taking lithium over time, 21 our study found a significant decrease in CC lactate concentrations after 6 weeks of lithium monotherapy. In Friedman et al, 21 subjects with BD were not evaluated under a specific duration of treatment or mood state, which may account for the difference with the present study in terms of the longitudinal effects of lithium. However, similar to our findings, they showed no differences in brain lactate levels in BD subjects taking lithium compared with control subjects. Despite no statistical significance, lactate posttreatment was lower (0.14) compared with control subjects (0.18), which could be due to lithium-inducing hypernormalization of brain lactate. The observed beneficial actions of lithium on reducing anaerobic metabolism may contribute to the well-known neuroprotective effects of this agent. 31 In addition, evidence supports the role of lithium as a key modulator of mitochondrial function and cellular energy metabolism, [18] [19] [20] which was supported by the present findings. Lithium also seems to normalize these changes by shifting back to glycolysis, limiting lactate production and improving mitochondrial respiration. 11 It may be hypothesized that the effects of lithium on brain energy production underlie its antidepressant and mood-stabilizing properties. Our results suggest that lithium acts by reducing the shift from aerobic to anaerobic metabolism observed in BD 11, 32 ; however, this shift did not correlate with clinical improvement. One explanation is the considerable number of good responders to lithium in the present sample, based on a potential enriched sample selected, which aimed to allow the use of lithium monotherapy and to avoid possible dropouts. The small number of nonresponders may have precluded the ability to detect differences in mean lactate levels.
The strengths of this study include the longitudinal design with both clinical and imaging measurements, and this is one of the largest within-subjects study in BD. The study had homogeneous duration of treatment, specific use of lithium monotherapy, exclusion of comorbid conditions (eg, substance abuse/ dependence), and all BD patients were drug-free (80.0% of whom were treatment naive). In addition, the fact that we recruited a sample with a relatively short duration of illness (mean, 36 months) and no concurrent substance use disorders limits the possibility that our results could have been influenced by confounding factors, such as illness staging and/or co-occurring long-term comorbidities. Differently from the previous studies that assessed brain lactate levels in subjects with BD, 5,12,13 we used a within-subject longitudinal design with a systematic clinical follow-up in which the 1 H-MRS examinations were repeated after a specific period. Finally, the use of a long echo time improves the resolution of the lactate resonance, and summing across voxels improves the SNR. It needs to be pointed that we are reporting relative ratios of lactate to Cr signals and not absolute concentrations, so any changes in these ratios could be theoretically also related to changes in Cr or metabolite relaxation times. However, this is very unlikely. An extensive and thorough study 5 measuring absolute metabolite concentrations and T2 relaxation times in different brain regions with different tissue compositions concluded that there were no differences between BD medication-free patients and control subjects in Cr, Cho, NAA, and myo-inositol concentrations or relaxation times. The only differences were found for lactate and glutamate + glutamine concentrations. Therefore, to measure lactate relative to Cr is a common practice and has been used previously to measure longitudinal lactate changes in BD patients. 13 Some limitations in our study merit discussion. First, the duration of lithium treatment was relatively short. However, most potential good responders to lithium had achieved a response, and most had mild to moderate depression at baseline. In addition, this was an openlabel trial, which might limit potential conclusions that can be drawn from clinical outcomes (which could be related to lithium's effects or natural course of illness). Second, we enrolled a convenience sample that could have selected good or excellent lithium responders. Lastly, our study was uncontrolled, and healthy volunteers had only 1 scan.
Overall, our findings reinforce the presence of altered metabolic activity in the brain leading to a shift toward lactic acidosis during mood episodes. They also support a key role for lithium in normalizing this dysfunctional brain energy state through direct effects at mitochondrial function. The present findings reinforce that lactate may be a state biomarker in BD and that mitochondrial modulators might offer promising treatment targets in the illness, especially in long-term treatment. Further studies with longer duration and larger samples are required to provide further evidence for the key mechanisms of lithium's modulatory effects on brain mitochondrial and redox activity in BD and its association with clinical outcomes.
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